Skip to Content
Find More Like This
Return to Search

Annexin A9 (ANXA9) biomarker and therapeutic target in epithelial cancer

United States Patent

June 12, 2012
View the Complete Patent at the US Patent & Trademark Office
Lawrence Berkeley National Laboratory - Visit the Technology Transfer and Intellectual Property Management Department Website
Amplification of the ANXA9 gene in human chromosomal region 1q21 in epithelial cancers indicates a likelihood of both in vivo drug resistance and metastasis, and serves as a biomarker indicating these aspects of the disease. ANXA9 can also serve as a therapeutic target. Interfering RNAs (iRNAs) (such as siRNA and miRNA) and shRNA adapted to inhibit ANXA9 expression, when formulated in a therapeutic composition, and delivered to cells of the tumor, function to treat the epithelial cancer.
Hu; Zhi (El Cerrito, CA), Kuo; Wen-Lin (San Ramon, CA), Neve; Richard M. (San Mateo, CA), Gray; Joe W. (San Francisco, CA)
The Regents of the University of California (Oakland, CA)
12/ 412,304
March 26, 2009
STATEMENT OF GOVERNMENTAL SUPPORT This invention was made during work supported by the National Cancer Institute, through Grants CA 58207 and CA 64602 and during work supported by the U.S. Department of Energy under Contract No. DE-AC02-05CH11231. The government has certain rights in this invention.